Targeted Genetics Corp. received an undisclosed milestone payment from Amsterdam Molecular Therapeutics B.V. (AMT) under a licensing agreement that provides AMT with non-exclusive rights to Adeno-Associated Virus type 1 (AAV1), a serotype of AAV with the potential to treat lipoprotein lipase (LPL) deficiency. AMT recently initiated a pre-registration trial for AMT-011, an AAV1-based therapy for LPL deficiency, and anticipates commercialization of the product in 2009. LPL deficiency is a severe a...